Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study - PubMed (original) (raw)
Randomized Controlled Trial
. 2014 Dec;16(12):1239-46.
doi: 10.1111/dom.12377. Epub 2014 Sep 25.
Affiliations
- PMID: 25132212
- DOI: 10.1111/dom.12377
Randomized Controlled Trial
Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study
S Del Prato et al. Diabetes Obes Metab. 2014 Dec.
Abstract
Aims: To evaluate the long-term durability of the efficacy of alogliptin compared with glipizide in combination with metformin in people with type 2 diabetes inadequately controlled on stable-dose metformin.
Methods: This multicentre, double-blind, active-controlled study randomized 2639 patients aged 18-80 years to 104 weeks of treatment with metformin in addition to alogliptin 12.5 mg once daily (n = 880), alogliptin 25 mg once daily (n = 885) or glipizide 5 mg once daily, titrated to a maximum of 20 mg (n = 874). The primary endpoint was least square mean change from baseline in HbA1c level at 104 weeks.
Results: The mean patient age was 55.4 years, the mean diabetes duration was 5.5 years and the mean baseline HbA1c was 7.6%. HbA1c reductions at week 104 were -0.68%, -0.72% and -0.59% for alogliptin 12.5 and 25 mg and glipizide, respectively [both doses met the criteria for non-inferiority to glipizide (p<0.001); alogliptin 25 mg met superiority criteria (p=0.010)]. Fasting plasma glucose concentration decreased by 0.05 and 0.18 mmol/l for alogliptin 12.5 and 25 mg, respectively, and increased by 0.30 mmol/l for glipizide (p < 0.001 for both comparisons with glipizide). Mean weight changes were -0.68, -0.89 and 0.95 kg for alogliptin 12.5 and 25 mg and glipizide, respectively (p < 0.001 for both comparisons with glipizide). Hypoglycaemia occurred in 23.2% of patients in the glipizide group vs. 2.5 and 1.4% of patients in the alogliptin 12.5 and 25 mg groups, respectively. Pancreatitis occurred in one patient in the alogliptin 25 mg group and three in the glipizide group.
Conclusions: Alogliptin efficacy was sustained over 2 years in patients with inadequate glycaemic control on metformin alone.
Keywords: DPP-IV inhibitor; antidiabetic drug; diabetes mellitus; glycaemic control; incretin therapy; randomised trial.
© 2014 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
Similar articles
- Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study.
Rosenstock J, Wilson C, Fleck P. Rosenstock J, et al. Diabetes Obes Metab. 2013 Oct;15(10):906-14. doi: 10.1111/dom.12102. Epub 2013 Apr 18. Diabetes Obes Metab. 2013. PMID: 23531118 Clinical Trial. - Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus.
Del Prato S, Fleck P, Wilson C, Chaudhari P. Del Prato S, et al. Diabetes Obes Metab. 2016 Jun;18(6):623-7. doi: 10.1111/dom.12643. Epub 2016 Mar 31. Diabetes Obes Metab. 2016. PMID: 26865535 Clinical Trial. - Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study.
Seino Y, Miyata Y, Hiroi S, Hirayama M, Kaku K. Seino Y, et al. Diabetes Obes Metab. 2012 Oct;14(10):927-36. doi: 10.1111/j.1463-1326.2012.01620.x. Epub 2012 Jun 5. Diabetes Obes Metab. 2012. PMID: 22583697 Clinical Trial. - Alogliptin: safety, efficacy, and clinical implications.
Marino AB, Cole SW. Marino AB, et al. J Pharm Pract. 2015 Feb;28(1):99-106. doi: 10.1177/0897190014522063. Epub 2014 Feb 13. J Pharm Pract. 2015. PMID: 24532820 Review. - Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus.
Jarvis CI, Cabrera A, Charron D. Jarvis CI, et al. Ann Pharmacother. 2013 Nov;47(11):1532-9. doi: 10.1177/1060028013504076. Ann Pharmacother. 2013. PMID: 24285765 Review.
Cited by
- Bone Fragility in Diabetes and its Management: A Narrative Review.
Leungsuwan DS, Chandran M. Leungsuwan DS, et al. Drugs. 2024 Sep;84(9):1111-1134. doi: 10.1007/s40265-024-02078-5. Epub 2024 Aug 5. Drugs. 2024. PMID: 39103693 Review. - Assessing the Risk of Bias in Randomized Clinical Trials With Large Language Models.
Lai H, Ge L, Sun M, Pan B, Huang J, Hou L, Yang Q, Liu J, Liu J, Ye Z, Xia D, Zhao W, Wang X, Liu M, Talukdar JR, Tian J, Yang K, Estill J. Lai H, et al. JAMA Netw Open. 2024 May 1;7(5):e2412687. doi: 10.1001/jamanetworkopen.2024.12687. JAMA Netw Open. 2024. PMID: 38776081 Free PMC article. - A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications.
Haddad F, Dokmak G, Bader M, Karaman R. Haddad F, et al. Life (Basel). 2023 Apr 14;13(4):1012. doi: 10.3390/life13041012. Life (Basel). 2023. PMID: 37109541 Free PMC article. Review. - Systematic review and meta-analysis of head-to-head trials comparing sulfonylureas and low hypoglycaemic risk antidiabetic drugs.
Volke V, Katus U, Johannson A, Toompere K, Heinla K, Rünkorg K, Uusküla A. Volke V, et al. BMC Endocr Disord. 2022 Oct 19;22(1):251. doi: 10.1186/s12902-022-01158-5. BMC Endocr Disord. 2022. PMID: 36261824 Free PMC article. - Correction to: "Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: A Meta-Analysis".
Jeon WK, Kang J, Kim HS, Park KW. Jeon WK, et al. J Lipid Atheroscler. 2022 Jan;11(1):89-101. doi: 10.12997/jla.2022.11.1.89. Epub 2022 Jan 14. J Lipid Atheroscler. 2022. PMID: 35118026 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous